MikeyNJ
Posted - 7 minutes ago
$BBIO To make money in biopharmas, one needs to have a thesis and the ability to maintain their conviction despite the volatility in the underlying share price. BBIO has been a tough one to do this with, however, I strongly believe this is a big winner. This in my opinion is a 5 star pick. I have read the comparative data over and over. Acoramidas is superior to Tafamidas and Amvuttra. The Helios-B data for Amvuttra questions if it supports first line therapy. The market for ATTR-CM is estimated north of $8 billion. Acoramidas should get a significant share of that. Additionally, as we have stated before, BBIO upon approval, will get a $500 million milestone payment. There is also the pipeline that is showing promise. I bought more today. This stock is on sale.
Papermoon347
Posted - 1 hour ago
$BBIO Bulls and bears are fighting today.Bulls will prevail !
Capitulation_0
Posted - 1 hour ago
$BBIO Acting like, it'll sell off after Approval. Need show the market like $TGTX after approval.
Papermoon347
Posted - 2 hours ago
$BBIO Any thoughts on his price action ?
jesse77727
Posted - 15 hours ago
$BBIO t minus 9 days
Forbes502
Posted - 19 hours ago
$BBIO Bridgebio pharma Inc : JP Morgan cuts target price to $40 from $43
Jackie_O_
Posted - 22 hours ago
$BBIO Always risky with bios, but I'm in 😊
chadearic
Posted - 1 day ago
$BBIO wake me at 45
BioMan122
Posted - 1 day ago
$BBIO who says stock price will rise with approval? probably another sell on good news 🤡
Irish_lass
Posted - 1 day ago
$BBIO
roger120
Posted - 1 day ago
$BBIO No brainer FDA approval imo. People that take drug live longer. Once approved prime BO target.
If they go it alone $20B valuation within 18 months.
Papermoon347
Posted - 1 day ago
$BBIO Let's hope yesterday was the day we started heading north to the 30s just to start !
knowthyself
Posted - 1 day ago
$BBIO if approved, milestone payment is triggered; no need to raise cash
sampeper
Posted - 1 day ago
$BBIO chat gpt said: FDA processes, here's the assessment: ### **Factors Supporting a Positive Decision:** 1. **Strong Phase 3 Data:** - The results of the ATTRibute-CM study demonstrate significant improvements in mortality, hospitalizations, and quality of life. - Solid clinical data usually greatly increase the likelihood of approval. 2. **No Advisory Committee (AdCom):** - The absence of an AdCom suggests the FDA has no major concerns regarding safety or efficacy. - Historically, decisions made without an AdCom are more often positive. 3. **Rare Disease and Unmet Need:** - Drugs for rare conditions like transthyretin amyloid cardiomyopathy (ATTR-CM) often benefit from regulatory support, such as Orphan Drug designation. ### **Estimated Chances:** - Based on the analysis of past FDA decisions and the strength of the study data, the likelihood of Acoramidis receiving approval can be estimated at **80–90%**. - This assumes no unexpected issues arise during the final phase of th.
Jabed206
Posted - 1 day ago
$BBIO recent pdufa approvals impact on SP has been rubbish recently
J_shap
Posted - 1 day ago
$BBIO just casuals trading with their emotions and not using their brain. Loaded up even more no sweat
knowthyself
Posted - 1 day ago
$BBIO anyone understand what's going on here? No run-up. More like a run-down.
Article_AI
Posted - 1 day ago
$BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. https://www.stck.pro/news/BBIO/93596442/
RonIsWrong
Posted - 1 day ago
$BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [...] William Blair writes that reducing overall mortality is crucial for competing in the ATTR-CM market against Pfizer Inc’s tafamidis, which already includes proven mortality benefits on its label from the ATTR-ACT trial. The analyst writes, “While Bridge Bio continues to publish analyses of acoramidis demonstrating the TTR stabilizer is safe and efficacious, we deem an on-label claim to all-cause mortality benefit as an important factor for market share in the lucrative, but competitive, ATTR-CM space.” [...] BridgeBio’s marketing application is under FDA review, with a PDUFA action date of November 29, 2024
Irish_lass
Posted - 1 day ago
$BBIO November 29- PDUFA
“The prescribing community is eager to have another important treatment option given the remaining high unmet need for ATTR-CM patients.”
Key initial results from the OLE study, presented by Dr. Judge at AHA, show that continuous treatment with acoramidis led to:
A confirmed sustained improvement relative to placebo in time to first event (CVH or ACM) starting at Month 3 in ATTRibute-CM
A statistically significant reduction in ACM alone of 36% by Month 36 (p=0.009) and 34% by Month 42 (p=0.006), as assessed by the Stratified Cox proportional hazards model A significant reduction of composite ACM and CVH by 46% at Month 36 (p<0.0001) and 48% at Month 42 (p<0.0001), as assessed by negative binomial regression, building upon the previously presented 42% reduction at Month 30 in ATTRibute-CM.”
Papermoon347
Posted - 1 day ago
$BBIO Maybe better this Kennedy B.S. came to play out a bit now than the day Pdufa .
MikeyNJ
Posted - 1 day ago
$BBIO According to latest filings, 99% of the float is held by institutions. There is ten days remaining until the PDUFA deadline. Institutions are carefully risked and at this point, with a major catalyst close, most would prefer to buy after the event is out of the way at a higher price then to possibly risk bigger losses in the event of a negative outcome. The data to me is compelling and a negative FDA decision would be surprising. Analysts are positive with an average price target of $48. Assuming the FDA decision is positive, the price should at least get back above $30 where institutions should be buying hand over foot pushing the valuation toward those analysts target. Just look at the basic fundamentals. Upon approval, BBIO will receive a milestone payment of $500 million bringing its cash position close to $1 billion. The ATTR-CM market is estimated to be at least $8 billion and BBIO will get its share based on superior data. In my opinion this is a great buy. We will see.
Gravitationalsingularity
Posted - 2 days ago
$BBIO The double bottom is at $21.62. It was ten cents shy of that number earlier, but could go for a retest. Seven business days until PDUFA. Seven. If it gets awarded, the milestone payments will flow and a tap into the up to $20B ATTR market will have been installed. Seven days folks. Don't let a small shave off of the top rattle you. Let them short.
J_shap
Posted - 2 days ago
$BBIO ouch this stock is tanking
Nosh
Posted - 2 days ago
$BBIO One of those names I really like and has never let me down...added here and would love to continue to add on dips...glty.
ringo2112
Posted - 2 days ago
$BBIO want to be pissed at the company, but I can't...good company good products, my whole strategy is based around biotech. did not realize Trump and RFK is anti pharma , or the consensus say's so....bio's as a sector getting beat up pretty bad right now....hope this gets approved and it takes off....would I still vote for Trump if I knew this previously? 100%
sampeper
Posted - 2 days ago
$BBIO Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis https://www.fiercebiotech.com/biotech/bridgebio-shows-more-positive-data-cardiomyopathy-candidate-acoramidis
jesse77727
Posted - 2 days ago
$BBIO even if your bullish bbio...report Sam please....he is notorious for span and also posting very old articles as if it's new.